JZL 184

JZL 184 is a potent, selective and irreversible MAGL inhibitor that blocks 2-Arachidonoylglycerol (2-AG) hydrolysis in brain membranes (IC50 of 8 nM) . JZL 184 displays >300-fold selectivity for MAGL over FAAH[1][2].

Product Specifications

CAS Number

[1101854-58-3]

UNSPSC

12352005

Hazard Statement

H301

Target

MAGL

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/JZL-184.html

Purity

99.46

Solubility

DMSO : ≥ 35 mg/mL

Smiles

OC(C1=CC=C(OCO2)C2=C1)(C3CCN(C(OC4=CC=C([N+]([O-])=O)C=C4)=O)CC3)C5=CC(OCO6)=C6C=C5

Molecular Formula

C27H24N2O9

Molecular Weight

520.49

Precautions

H301

References & Citations

[1]Long JZ, et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol. 2009 Jan;5 (1) :37-44.|[2]Pan B, et al. Blockade of 2-arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4- (dibenzo[d][1,3]dioxol-5-yl (hydroxy) methyl) piperidine-1-carboxylate (JZL184) Enhances retrograde endocannabinoid signaling. J Pharmacol Exp Ther. 2009 Nov;331 (2) :591-7.